Sampling and Testing of Packaged Products Sample Clauses

Sampling and Testing of Packaged Products. Cardinal Health is responsible in all cases for sending Purchaser batch records and samples for Purchaser’s review. Purchaser is responsible for all sampling and testing of the Packaged Products to assure that the Packaging and the Packaged Products are in conformity in all material respects with the Specifications set forth in the Purchase Order. Prior to delivering any shipment of Packaged Products, Cardinal Health shall provide Purchaser in all cases with a certificate of conformance and, additionally, in cases where Cardinal Health has performed any analytical testing of the Packaged Product, a certificate of analysis, in each case certifying that the Packaging and Packaged Products conform in all material respects to the Specifications. Purchaser, upon receipt of Packaged Products from Cardinal Health, shall have ten (10) business days or, in the case of defects not readily discernible without opening the Packaging or any components thereof, until the earlier of (i) thirty (30) days after Purchaser becomes aware of such defects or (ii) ninety (90) days after Purchaser receives such Packaged Products to inspect and reject such Packaged Products. Any Packaged Product that is not rejected by Purchaser within period set forth in the immediately preceding sentence shall be deemed to have been accepted by Purchaser. In the event Packaged Products do not conform in all material respects to the Specifications set forth in the relevant Purchase Order, Purchaser shall send to Cardinal Health via overnight delivery service or certified mail, return receipt requested, within three (3) days of discovery of the defect, a notice of rejection along with samples of the rejected Packaged Products. Packaged Products that Cardinal Health agrees are defective or non-conforming will be repackaged by Cardinal Health in accordance with Section 8(b). If Cardinal Health does not agree with Purchaser’s determination that the Packaging or Packaged Products fail to meet the Specifications in all material respects, the rejected Packaged Products shall be submitted to a mutually acceptable third party testing laboratory (which, unless otherwise agreed by the parties, shall be Lancaster Laboratories), which shall determine whether such Products conform in all material respects to the Specifications. The parties agree that such testing laboratory’s determination shall be final. Cardinal Health shall be responsible for the fees of such third party testing laboratory if such testing la...
Sample 1Sample 2
AutoNDA by SimpleDocs
Sampling and Testing of Packaged Products. If Company believes that any Packaged Product received under this Agreement does not conform to the Packaging warranties of *** Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission.
Sample 1
Sampling and Testing of Packaged Products. AMAG is responsible for all sampling and testing of the Packaged Products to assure that the Packaged Products are in conformity in all material respects with the Specifications. AMAG, upon receipt of Packaged Products from Catalent, shall have ten (10) days to inspect or otherwise evaluate such Packaged Products. Any Packaged Product that is not rejected by AMAG within thirty (30) days of receipt from Catalent shall be deemed to have been accepted by AMAG. In the event AMAG rejects such delivery, AMAG shall send to Catalent, via overnight delivery service or certified mail, return receipt requested, within three (3) days of discovery of the defect, a notice of rejection along with samples of the rejected Packaged Products. In the event Catalent agrees with AMAG’s rejection of the Packaged Product Catalent, at its expense, shall repackage such Product in accordance with Section 7.2. If Catalent does not agree with AMAG’s determination that the Packaged Products are non-conforming, the rejected Packaged Products shall be submitted to a mutually acceptable third party testing laboratory, which shall determine whether such Products at the time of delivery did conform to the Specifications and were manufactured in accordance with the terms of this Agreement and the Quality Agreement. The parties agree that such testing laboratory’s determination shall be final and the costs of such testing shall be paid by the non-prevailing party.
Sample 1

Related to Sampling and Testing of Packaged Products

  • Product Testing Upon request, Customer shall provide Operator a laboratory report for each Product delivery by Customer or Customer’s supplier. Operator will not be obligated to receive Contaminated Product for throughput through the Pipelines, nor will Operator be obligated to accept Product that fails to meet the applicable quality specifications for the Berths under the BAUTA and any Terminal Service Orders issued thereunder.

  • Inspection and Testing 7.5.1 Meters, data acquisition, and related protection equipment at Generator's Interconnection Point shall be tested at least biennially by Generator in accordance with the provisions for meter testing as established in American National Standard Institute Code for Electricity Metering (ANSI) Standard C12.16 for Solid State Electricity Meters, as the same may be updated from time to time. Representatives of each Party shall be afforded an opportunity to witness such tests.

  • Product Specifications The Company agrees that all Products sold to Xxxx hereunder shall conform to the respective specifications set forth on Schedule A or to such other specifications as are from time to time agreed upon by the Parties.

  • Quality Specifications SANMINA-SCI shall comply with the quality specifications set forth in its Quality Manual, incorporated by reference herein, a copy of which is available from SANMINA-SCI upon request.

  • Testing Landlord shall have the right to conduct annual tests of the Premises to determine whether any contamination of the Premises or the Project has occurred as a result of Tenant’s use. Tenant shall be required to pay the cost of such annual test of the Premises; provided, however, that if Tenant conducts its own tests of the Premises using third party contractors and test procedures acceptable to Landlord which tests are certified to Landlord, Landlord shall accept such tests in lieu of the annual tests to be paid for by Tenant. In addition, at any time, and from time to time, prior to the expiration or earlier termination of the Term, Landlord shall have the right to conduct appropriate tests of the Premises and the Project to determine if contamination has occurred as a result of Tenant’s use of the Premises. In connection with such testing, upon the request of Landlord, Tenant shall deliver to Landlord or its consultant such non-proprietary information concerning the use of Hazardous Materials in or about the Premises by Tenant or any Tenant Party. If contamination has occurred for which Tenant is liable under this Section 30, Tenant shall pay all costs to conduct such tests. If no such contamination is found, Landlord shall pay the costs of such tests (which shall not constitute an Operating Expense). Landlord shall provide Tenant with a copy of all third party, non-confidential reports and tests of the Premises made by or on behalf of Landlord during the Term without representation or warranty and subject to a confidentiality agreement. Tenant shall, at its sole cost and expense, promptly and satisfactorily remediate any environmental conditions identified by such testing in accordance with all Environmental Requirements. Landlord’s receipt of or satisfaction with any environmental assessment in no way waives any rights which Landlord may have against Tenant.

  • Labeling and Packaging BTG shall label and package the Bulk Product in accordance with Legal Requirements applicable to pharmaceutical products shipped in bulk for further processing, labeling, or repackaging.

  • Tests and Preclinical and Clinical Trials The preclinical studies and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, and are intended to be submitted to the U.S. Food and Drug Administration (the “FDA”) or other comparable government entities, were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, current Good Clinical Practices and Good Laboratory Practices and any applicable rules and regulations of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate and complete in all material respects and fairly present the data derived from such studies and trials; except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any studies or trials, the results of which the Company believes reasonably call into question the study or trial results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical stage of development; and, except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company has not received any written notices or written correspondence from the FDA or any governmental entity requiring the termination or suspension of any preclinical studies or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

  • Product The term “

  • Review of Materials During the term of this Agreement, Client shall ensure that all prospectuses, statements of additional information, registration statements, proxy statements, reports to shareholders, advertising and sales literature or other materials prepared for distribution to Fund shareholders or the public, which refer to the Subadviser in any way, prepared by employees or agents of Client or its affiliates are consistent with information previously provided by Subadviser. Subadviser shall promptly notify the Client of any changes to information pertaining to the Subadviser and stated in the materials described in this Section 6(g).

  • Packaging and Labeling 11.1 Company shall provide packaging and labeling specifications that call out clear labeling requirements.

Time is Money Join Law Insider Premium to draft better contracts faster.